Compare · A vs TXG
A vs TXG
Side-by-side comparison of Agilent Technologies Inc. (A) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $43.37B, about 5.3x TXG ($8.14B).
- TXG has been more active in the news (12 items in the past 4 weeks vs 3 for A).
- Both have 25 recent analyst ratings on file.
- Company
- Agilent Technologies Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $43.37B
- $8.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2019
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 25
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest A
- Agilent Introduces the Cary 635 FTIR Spectrometer
- Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
Latest TXG
- Chief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)
- 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
- Chief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Taich Adam sold $1,081,853 worth of shares (17,166 units at $63.02), decreasing direct ownership by 5% to 362,732 units (SEC Form 4) to cover withholding tax
- Officer Hindson Benjamin J. sold $870,860 worth of shares (13,818 units at $63.02), decreasing direct ownership by 3% to 488,182 units (SEC Form 4) (withholding obligation)
- Director Suliman Shehnaaz sold $140,478 worth of shares (2,207 units at $63.65) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 29,515 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 4,000 shares, decreasing direct ownership by 0.36% to 1,104,380 units (SEC Form 4)
- Director Teichmann Sarah A. sold $432,279 worth of shares (7,551 units at $57.25) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 28,058 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.